The Age Nobody Talks About: Migraine After 60

The Lie You Were Told

Someone told you it would end.

Maybe it was a neurologist, tired at the end of a long clinic day. Maybe it was a friend who’d gotten lucky. Maybe it was the internet, optimistic and half-wrong. The message was consistent: hang on. Get through menopause. Age out of this. The migraines will fade.

For many people, they do. But for a number that medicine rarely acknowledges, something different happens. The migraines don’t disappear after 60. They transform — quieter in some ways, stranger in others, and newly complicated by a body that no longer responds to treatment the way it once did.

I’ve lived with migraine for 30 years. I’ve watched this myth comfort people and mislead them in equal measure. The truth is harder and more useful.

A 2022 systematic review found that elderly adults carry a migraine burden of 16.4% — nearly as high as the 17.9% documented in 18–44-year-olds.^[1] That figure should be everywhere. Instead, it’s almost nowhere. Older migraineurs are underrepresented in clinical trials, undertreated in practice, and regularly told that what they’re experiencing doesn’t quite match the textbooks — because the textbooks weren’t written with them in mind.

That’s the gap this article is here to close.

What Changes — and What Doesn’t

After 60, migraine rarely holds its shape.

The most documented shift is in the character of the pain itself. In younger adults, migraine tends to be unilateral — one-sided, pounding, impossible to ignore. After 60, it often becomes bilateral. Duller. Easier to dismiss as tension headache, aging, or just a bad day.^[2] The throbbing softens. Nausea may lessen. What doesn’t necessarily change is how often attacks arrive, or how thoroughly they can derail a day.

Then there’s aura. For some women, it increases after menopause — the visual zigzags and tingling sensations that signal a coming storm become more frequent, not less.^[2] For others, aura begins arriving without headache at all. These “silent migraines” are disorienting in a particular way: the visual disturbances appear, the sensory symptoms move through, and then — nothing. No pain. Just the unsettling awareness that your brain did something unusual and you’re not sure what it means.

One critical note: if aura without headache appears for the first time after age 50 — with no prior migraine history — treat it as a transient ischemic attack until a neurologist or cardiologist rules that out. Do not self-diagnose this as “just migraine” without a medical evaluation first.

Estrogen is part of the broader story. It plays a complex modulatory role in migraine throughout a woman’s life; the hormonal instability of perimenopause often intensifies attacks, and the stable low-estrogen state that follows brings genuine relief for many — but not all.^[1][2] Vascular changes, neuronal aging, and cumulative sensitization of the trigeminal pain system all contribute to a clinical picture that a landmark 2022 Lancet Neurology review described as “not well characterised.”^[2]

What is well characterised is the consequence: more comorbidities, more medications in the daily routine, and therefore more complexity in treating the migraine itself.

When the Headache Is Something Else

This is where migraine after 60 becomes genuinely dangerous — not because the attacks themselves are more severe, but because something else may be wearing their mask.

Giant cell arteritis is the diagnosis that cannot be missed. It’s an inflammatory disease of medium and large arteries — most commonly the temporal artery running along the side of the skull — and it presents with headache in 70 to 90 percent of cases.^[5] The pain is often throbbing. Often temporal. Close enough to migraine that one documented case involved a patient who spent a full year being treated for migraine — receiving amitriptyline, propranolol, and flunarizine — before a temporal artery biopsy revealed the actual diagnosis.^[4]

That year mattered. Untreated giant cell arteritis can cause permanent vision loss. Its mortality from stroke and myocardial infarction sits at approximately 1–3%.^[5] The diagnostic delay averages over nine weeks — time in which irreversible damage accumulates.^[16]

The distinguishing features are specific: scalp tenderness, pain when combing your hair, jaw pain while chewing or speaking, visual disturbances, and systemic symptoms — fever, unexplained weight loss, profound fatigue, shoulder and hip stiffness. Elevated ESR and CRP are the key laboratory signals. Temporal artery biopsy or imaging confirms the diagnosis.

The second impostor is stroke. Migraine with aura is an established independent risk factor for ischemic stroke — and after 60, when vascular risk is already accumulating, the overlap between stroke symptoms and aura symptoms becomes clinically treacherous.^[1] Sudden and severe headache, the worst of your life; aura that lasts longer than 60 minutes; weakness or speech difficulty that doesn’t resolve — these are emergencies, not migraine abortives.

Is This Migraine — or Something More Dangerous?

When you’re in pain and frightened, you don’t read paragraphs. You scan. Use this table as a quick reference — and as a reason to call your doctor.

This table is a quick reference guide, not a diagnostic tool. Always consult a physician for evaluation.

The Medication Problem Nobody Explains Clearly

Let’s be honest about something most conversations avoid: many of the drugs that managed your migraine for decades may no longer be appropriate after 60.

Triptans — sumatriptan, rizatriptan, eletriptan — are labeled as contraindicated or not recommended past 65, and specifically in anyone with cardiovascular disease, cerebrovascular disease, uncontrolled hypertension, or peripheral artery disease.^[6] The mechanism is the problem: triptans work by constricting blood vessels, and in a younger, vascularly healthy person this is manageable. In someone whose arteries have accumulated decades of wear, that same constriction can tip the balance.

A large French pharmacoepidemiological study of triptan users aged 65 and older — drawing from a national health insurance database — found that the absolute risk of hospitalization from vascular events remained low, but consistently highlighted the need for rigorous individual cardiovascular evaluation before continuing these medications past that threshold.^[6] A separate Austrian nationwide study found that 43.6% of older triptan users already carried a vascular diagnosis or were on vascular medications — yet were still receiving triptan prescriptions.^[7]

NSAIDs — ibuprofen, naproxen — face their own calculus. Gastrointestinal bleeding risk climbs with age. Kidney function declines. The long list of medications many older adults take for cardiovascular and metabolic conditions multiplies interaction risk. Acetaminophen is the safest acute option after 60, with the honest caveat that it’s a weaker weapon against moderate-to-severe attacks.^[8]

The safe medication window narrows precisely when the need for effective treatment remains unchanged. That tension is real — and it’s why the next development matters enormously.

The New Hope: CGRP Antibodies After 65

Here, the news is unambiguously good.

Anti-CGRP monoclonal antibodies — erenumab, fremanezumab, galcanezumab, eptinezumab — are the first migraine-specific preventive medications in history. They block calcitonin gene-related peptide, the neuropeptide at the center of migraine’s pain cascade. They carry none of the vasoconstriction that makes triptans problematic in older adults. They don’t sedate. They don’t interact with antihypertensives, anticoagulants, or statins in the ways that older preventives do.

A 2025 real-world study from the Cleveland Clinic — among the first specifically examining patients 65 and older — found no statistically significant difference in efficacy or tolerability between the over-65 and under-65 groups across erenumab, fremanezumab, and galcanezumab, in both episodic and daily migraine.^[9] Age alone, the researchers concluded, should not disqualify a patient from these treatments.

A comprehensive 2025 review confirmed sustained long-term safety and efficacy across all four antibodies, with tolerability that consistently outperforms older non-specific preventives like valproate or amitriptyline.^[10] In 2024, the American Headache Society updated its consensus to recommend CGRP antibodies as first-line options for patients with at least moderate disability — a meaningful shift from the previous “after failing two other treatments” requirement that had delayed access for years.^[10]

For the older migraineur who has exhausted the safer options from the traditional pharmacopoeia, this is not a small development.

What Medicine Still Forgets

There’s a dimension to migraine at 60 that rarely appears in clinical guidelines. It doesn’t have a billing code. But it shapes outcomes more than almost any pharmacological variable.

You have been living with this condition for years — possibly decades. You’ve built coping structures around it. Negotiated your relationships inside it. Shaped your career, your social life, your self-concept in its long shadow. After 60, those structures often shift at the same time the migraine shifts. Retirement disrupts routine — and routine is one of migraine management’s most reliable tools. Children leave. Social networks contract. Sleep architecture changes. Grief enters. Each of these is a potential trigger, and each intersects with how pain is experienced and how much suffering surrounds it.

This is where psychology makes its case.

Acceptance and Commitment Therapy (ACT), developed by Dr. Steven Hayes at the University of Nevada, has accumulated one of the most robust evidence bases in chronic pain psychology. Its core insight is counterintuitive: instead of fighting pain — controlling it, eliminating it, defining yourself by your struggle against it — the goal is to reduce the suffering that surrounds the pain. To disentangle who you are from what visits you. Dr. Russ Harris, one of ACT’s foremost clinical communicators, frames this as building psychological flexibility: the capacity to move toward what matters to you, even while pain is present.

The data support this framing. A 2024 meta-analysis of 21 RCTs found that ACT produced significant improvement in pain interference, functional impairment, pain acceptance, and depression in chronic pain patients.^[12] A systematic review specifically examining older adults found that they were less likely to drop out of ACT than younger patients — a finding researchers attributed to older adults’ deeper familiarity with acceptance as a life skill.^[11]

Cognitive Behavioral Therapy (CBT) adds a different but complementary dimension: identifying and restructuring the thought patterns that amplify pain’s impact. A 2025 systematic review and meta-analysis of 50 trials found that CBT, relaxation training, and mindfulness-based interventions each reduced headache frequency in adults with migraine — with mindfulness specifically outperforming education alone for migraine disability.^[14] A meta-analysis focused on older adults with chronic pain found statistically significant reductions in both pain intensity and catastrophizing from CBT-based interventions, with group-delivered formats showing the largest effects.^[13]

The practical conclusion is unambiguous: if you are managing migraine at 60 purely with medication, you are using only part of the available toolkit.

A Practical Map Forward

Managing migraine after 60 means updating the strategy to match where you actually are — not where you were at 35, and not where clinical guidelines assume you are.